Boxer Capital Management LLC Acquires New Shares in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Boxer Capital Management LLC acquired a new position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 506,000 shares of the company's stock, valued at approximately $1,083,000. Boxer Capital Management LLC owned about 0.89% of Black Diamond Therapeutics at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC lifted its position in shares of Black Diamond Therapeutics by 201.9% in the 3rd quarter. Barclays PLC now owns 78,151 shares of the company's stock worth $339,000 after buying an additional 52,265 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Black Diamond Therapeutics by 12.2% in the third quarter. Geode Capital Management LLC now owns 944,877 shares of the company's stock worth $4,111,000 after acquiring an additional 102,445 shares during the last quarter. SG Americas Securities LLC acquired a new position in Black Diamond Therapeutics in the fourth quarter valued at approximately $42,000. Rhumbline Advisers boosted its stake in Black Diamond Therapeutics by 14.9% in the fourth quarter. Rhumbline Advisers now owns 56,135 shares of the company's stock valued at $120,000 after acquiring an additional 7,290 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of Black Diamond Therapeutics by 46.1% during the fourth quarter. Bank of New York Mellon Corp now owns 207,074 shares of the company's stock valued at $443,000 after purchasing an additional 65,341 shares during the last quarter. Institutional investors and hedge funds own 95.47% of the company's stock.

Black Diamond Therapeutics Stock Up 5.5 %

Shares of Black Diamond Therapeutics stock traded up $0.08 during trading on Wednesday, hitting $1.55. The stock had a trading volume of 210,758 shares, compared to its average volume of 1,470,044. Black Diamond Therapeutics, Inc. has a 1 year low of $1.20 and a 1 year high of $7.50. The company has a market capitalization of $87.57 million, a PE ratio of -1.16 and a beta of 2.63. The stock has a 50 day simple moving average of $1.61 and a 200 day simple moving average of $2.18.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. As a group, equities analysts expect that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on BDTX shares. HC Wainwright upped their price target on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, March 18th. Stifel Nicolaus dropped their price target on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Finally, Wedbush reiterated an "outperform" rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a research report on Wednesday, March 19th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $14.60.

Insider Transactions at Black Diamond Therapeutics

In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the business's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total value of $11,973,484.44. Following the transaction, the insider now owns 2,733,547 shares in the company, valued at $5,658,442.29. The trade was a 67.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 8.87% of the stock is owned by insiders.

Black Diamond Therapeutics Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.